NEW news 1.25 million of equity gained by institutional investors buying at 0.90 This corroborates that this company is something truly worth investing in.
Yes I agree. solid investment. short term investors will miss out on the real profit margins by selling before buyout or major partnership. This is the kind of stock to just put in the sock drawer for a while and aim for collecting long term gains with.
Most big pharma buy out targets are those who are in the late phase 2 and early phase 3 stage of the development.
Looking forward to seeing where things go with this stock, im definitly not worried about this one.
Market Data 
Markets 
AI
